SCHEMBL6662088

SCHEMBL6662088

CCOC(=O)Nc1cc(NS(=O)(=O)CC)c(C#N)cc1F

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NLRP3 Q96P20 1/20 0.44
PGR P06401 2/20 0.42
CYP1A2 P05177 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.40
AR P10275 1/20 0.40
MRGPRX1 Q96LB2 5/20 0.39
ALDH1A1 P00352 2/20 0.39
GAA P10253 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
KCNQ3 O43525 1/20 0.37
KCNQ2 O43526 1/20 0.37
KCNQ4 P56696 1/20 0.37
KCNQ5 Q9NR82 1/20 0.37
PSIP1 O75475 1/20 0.37
BRD4 O60885 1/20 0.36
HPGD P15428 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8333678 0.83 ALDH1A1 (0.50) NLRP3CYP1A2CYP2C9CYP2C19SMN1; SMN2
SCHEMBL5847244 0.82 NLRP3 (0.49) NLRP3CYP1A2CYP2C9CYP2C19SMN1; SMN2
SCHEMBL404508 0.82 NLRP3 (0.51) NLRP3CYP1A2CYP2C9CYP2C19SMN1; SMN2
SCHEMBL6663898 0.81 CYP1A2 (0.43) CYP1A2CYP2C9CYP2C19SMN1; SMN2MRGPRX1
SCHEMBL9120354 0.81 ALDH1A1 (0.46) CYP1A2CYP2C9CYP2C19SMN1; SMN2MRGPRX1
SCHEMBL406273 0.80 NLRP3 (0.49) NLRP3CYP1A2CYP2C9CYP2C19SMN1; SMN2
SCHEMBL8054362 0.79 PGR (0.39) PGRARMRGPRX1PSIP1BRD4
SCHEMBL6573122 0.79 PGR (0.50) PGRCYP2C9CYP2C19ARALDH1A1
SCHEMBL7753799 0.78 PGR (0.45) PGRARPSIP1BRD4HPGD
SCHEMBL8190834 0.77 NLRP3 (0.41) NLRP3CYP1A2CYP2C9CYP2C19SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1244615-B1 METHOD FOR PRODUCING N-SUBSTITUTED 2,4-DIAMINO-5-FLUORO BENZONITRILES AND NOVEL INTERMEDIATES BAYER CROPSCIENCE AG (DE) 2004-08-11 EP disclosed
US-20030017948-A1 Method for producing n-substituted 2,4-diamino-5-fluoro benzonitriles and novel intermediates BAYER AKTIENGESELLSCHAFT (DE) 2003-01-23 US disclosed
EP-1244615-A1 METHOD FOR PRODUCING N-SUBSTITUTED 2,4-DIAMINO-5-FLUORO BENZONITRILES AND NOVEL INTERMEDIATES Bayer Aktiengesellschaft (DE) 2002-10-02 EP disclosed
WO-2001047873-A1 METHOD FOR PRODUCING N-SUBSTITUTED 2,4-DIAMINO-5-FLUORO BENZONITRILES AND NOVEL INTERMEDIATES BAYER AKTIENGESELLSCHAFT (DE) 2001-07-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030017948-A1 Method for producing n-substituted 2,4-diamino-5-fluoro benzonitriles and novel intermediates DDT, PFAS, DAO NLRP3 2373/4885PGR 4770/4885CYP1A2 79/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.